Actinogen Medical Limited · ASX:ACW

Actinogen Medical — Shareholder Meeting (November 2016)

17 slides from Actinogen Medical's shareholder meeting presentation, Nov 30, 2016

  1. Slide 1: Annual General Meeting

    For personal use only ANNUAL GENERAL MEETING N o v 3 0 th 2 0 1 6 Dr. Bill Ketelbey CEO & Managing Director

  2. Slide 2: Disclaimer

    DISCLAIMER For personal use only This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all inform

  3. Slide 3: Focus on inhibiting cortisol production for Alzheimer's disease

    For personal use only FocusingFocusing on an on innovative approach, an innovative approach, through the inhibition of cortisol production, for treating Alzheimer's disease and through the inhibition of cortisol production, cognitive impairment in chronic neurodegenerative and for treating Alzheimer

  4. Slide 4: Alzheimer's disease is emerging as the most significant health challenge of our time

    ALZHEIMER’S DISEASE IS EMERGING AS • Leading cause of death in the UK and Europe • Second only to heart disease in Australia THE MOST SIGNIFICANT HEALTH • Of the top ten leading fatal illnesses, Alzheimer's remains the only one that cannot CHALLENGE OF OUR TIME For personal use only be prevented, tr

  5. Slide 5: Alzheimer's drug-development pipeline

    ALZHEIMER’S DRUG- DEVELOPMENT PIPELINE: DISEASE-MODIFYING IMMUNOTHERAPY 2016 For personal use only 93 DRUGS IN • 74% biopharma sponsored CLINICAL TRIALS • 50% amyloid targeted SYMPTOMATIC DISEASE- AGENTS MODIFYING 60 SMALL 50 MOLECULES 40 30 20 10 0 Trial Data Phase I Phase II Phase III Source: clin

  6. Slide 6: Alzheimer's disease pipeline: targets and stage of development

    ALZHEIMER’S DISEASE PIPELINE TARGETS AND STAGE OF DEVELOPMENT For personal use only AD candidates in active clinical development Therapeutic Mechanism Classes Phase I Phase II Phase III Classes 11β-HSD1 inhibitor 1 1 - SYMPTOM Neuroprotective 5 13 1 RELIEF Neurotransmitter based 3 13 6 Anti-amyloid

  7. Slide 7: Drug discovery and development: a long, risky road

    DRUG DISCOVERY 15 YEARS AND $1.5BN For personal use only PRE-DISCOVERY DRUG DISCOVERY & DEVELOPMENT: A LONG, RISKY ROAD 7 Source: Pharmaceutical Research and Manufacturers of America

  8. Slide 8: Recent publications confirm association between cortisol and Alzheimer's disease

    RECENT PUBLICATIONS CONFIRM ASSOCIATION For personal use only BETWEEN CORTISOL AND ALZHEIMER’S DISEASE 8

  9. Slide 9: Plasma cortisol, amyloid-β, and cognitive decline in preclinical Alzheimer's disease

    PLASMA CORTISOL, AMYLOID-Β, AND COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A 6-year prospective cohort study For personal use only Introduction Results Table 1: Demographic & clinical characteristics Aβ- low cortisol Aβ- high Aβ+ low Aβ+ high cortisol p Hypothalamic-pituitary-adrenal (HPA

  10. Slide 10: Actinogen's journey of discovery

    ACTINOGEN’S JOURNEY OF DISCOVERY For personal use only 11ẞ-HSD1 is highly Carbenoxolone is shown expressed in to enhance cognitive regions important function in elderly men for cognition and type II diabetics Xanamem™ (Sandeep et al., 2004) S TA R T data publication 11ẞ-HSD1 First First Xanamem™ and

  11. Slide 11: Xanamem: targeting elevated cortisol at the site of action

    For personal use only Xanamem™: TARGETING ELEVATED CORTISOL AT THE SITE OF ACTION 11

  12. Slide 12: Xanamem: symptomatic and disease modifying effects in mouse models

    Xanamem™ Symptomatic and disease modifying effects in mouse models For personal use only Cognition: treatment 28 days Amyloid clearance: treatment 28 days Control 43 21 Control 38 3 Treatment** 172 28 Treatment* 22 5 Latency to enter dark compartment (s) # of plaques per brain area Significant impro

  13. Slide 13: Xanamem development: proposed study design

    Xanamem DEVELOPMENT: proposed study design⃰ 174 For personal use only Treatment course 12 weeks Mild Alzheimer’s patients XanADu – Phase II double blind, Initiate XanADu at 10mg daily for 12 Trial run in randomised, placebo-controlled study to assess the efficacy of Xanamem™ weeks Vs placebo. Plan

  14. Slide 14: Outlook

    OUTLOOK Value Range by Development Stage For personal use only • Cash on hand (4C - Sept 2016): $6.6m Value US$ millions • Positive cashflow through to 2018 • Additional potential revenue: Financial • R&D rebate • EMDG • Other non-dilutive capital sources • XanADu budget estimate: TBD • Current mark

  15. Slide 15: Outlook: Actinogen and Xanamem on the world stage

    OUTLOOK ACTINOGEN and Xanamem™ – on the world stage For personal use only AAIC (Alzheimer's Association ICE (International Congress MMC (Mastering Medicinal International Congress) of Endocrinology) Chemistry) Xanamem and AIBL posters Oral presentation (Walker) Oral presentation (Webster) CTAD (Clin

  16. Slide 16: Outlook

    OUTLOOK For personal use only Xanamem™’s innovative, differentiated Patent protected to Excellent progress with research mechanism of action – reinforced by the 2031 – composition of planning and regulatory approval literature and KOLs matter XanADu and DCI patient Actinogens Experienced Alzheimer's

  17. Slide 17: Thank you

    For personal use only THANK YOU

Actinogen Medical — Shareholder Meeting (November 2016) on 6ix